The US FDA has approved BPaL, the TB Alliance’s treatment for drug-resistant tuberculosis (TB).
The US regulator gave the go-ahead to the TB Allliance’s Pretomanid Tablets as part of a three drug combo, as a treatment for highly treatment-resistant TB of the lungs.
“The threat of antimicrobial-resistant infections is a key challenge we face as a public health agency,” said FDA Principal Deputy Commissioner, Dr Amy Abernethy.
